Vyepti is a treatment for migraine, and its development and commercialization involve partnerships. Amneal Pharmaceuticals is involved with Vyepti, which was developed by Impel NeuroPharma and is indicated for the acute treatment of migraine with or without aura in adults [1].
What is Vyepti used for?
Vyepti is approved for the acute treatment of migraine with or without aura in adults [1]. Migraine is a neurological condition characterized by recurring headaches that can be accompanied by sensory disturbances, nausea, vomiting, and sensitivity to light and sound.
Who developed Vyepti?
Impel NeuroPharma developed Vyepti [1].
What is Amneal Pharmaceuticals' role with Vyepti?
Amneal Pharmaceuticals is a partner in the commercialization of Vyepti. In June 2023, Amneal announced it had entered into a strategic partnership with Impel NeuroPharma to commercialize Vyepti in the United States [1]. This partnership involves Amneal leveraging its commercial infrastructure to promote Vyepti to healthcare providers [1].
How does Vyepti work?
Vyepti is administered as an intravenous (IV) infusion. Its mechanism of action targets the calcitonin gene-related peptide (CGRP) pathway, which plays a key role in migraine pathophysiology [1]. By inhibiting CGRP, Vyepti helps to reduce neurogenic inflammation and vasodilation associated with migraine attacks.
When did Vyepti receive approval?
Vyepti received U.S. Food and Drug Administration (FDA) approval in February 2020 [2].
What are the alternatives to Vyepti for acute migraine treatment?
Other treatments for acute migraine attacks include triptans, CGRP receptor antagonists (e.g., rimegepant, ubrogepant), ditans, and non-steroidal anti-inflammatory drugs (NSAIDs). The choice of treatment often depends on individual patient characteristics, migraine severity, and co-existing conditions.
Where can I find more information on Vyepti and its patents?
Information on drug patents, including those related to Vyepti, can often be found on specialized patent tracking websites. For details on drug patents, you can consult resources like DrugPatentWatch.com [3].
---
Sources:
1. https://www.amneal.com/news-releases/amneal-and-impel-announce-strategic-partnership-to-commercialize-vyepti-for-migraine-in-the-united-states/
2. https://www.impelnp.com/news-releases/impel-neuropharma-announces-fda-approval-of-vyepti-cgrp-iv-infusion-for-the-acute-treatment-of-migraine-with-or-without-aura-in-adults/
3. https://drugpatentwatch.com/